GO
Loading...

Baxter International Inc

More

  • Final Glance: Medical Devices companies Monday, 18 Aug 2014 | 6:02 PM ET

    Allergan fell $2.65 or 1.7 percent, to $155.61. Baxter International Inc. rose$. 80 or 1.1 percent, to $75.21. Boston Scientific Corp. rose$. 18 or 1.4 percent, to $12.64.

  • Final Glance: Pharmaceuticals companies Monday, 18 Aug 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 80 or 1.1 percent, to $75.21. Bristol-Myers Squibb Co. rose$. 31 or. 6 percent, to $49.99. Hospira rose$. 46 or. 8 percent, to $55.48.

  • Early Glance: Pharmaceuticals companies Monday, 18 Aug 2014 | 10:29 AM ET

    Baxter International Inc. rose$. 81 or 1.1 percent, to $75.22. Bristol-Myers Squibb Co. rose$. 13 or. 3 percent, to $49.81. Hospira rose$. 76 or 1.4 percent, to $55.78.

  • Early Glance: Medical Devices companies Monday, 18 Aug 2014 | 10:29 AM ET

    Allergan fell $1.26 or. 8 percent, to $157.00. Baxter International Inc. rose$. 81 or 1.1 percent, to $75.22. Boston Scientific Corp. rose$. 14 or 1.1 percent, to $12.60.

  • NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.

  • The FDA, which had raised concerns that some patients developed antibodies to one component of the treatment, is not obliged to follow the advice of its advisory panels but typically does so. The FDA had asked whether certain subgroups of patients, such as pregnant women, should be excluded.

  • UPDATE 2-Gambro acquisition boosts Baxter's sales Thursday, 17 Jul 2014 | 1:30 PM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

  • UPDATE 1-Medical products boost Baxter's sales Thursday, 17 Jul 2014 | 8:33 AM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly earnings and revenue, helped by surging sales in its medical products division. Net adjusted income rose to $692 million, or $1.26 per share in the second quarter ended June 30, from $639 million, or $1.16 per share, a year earlier.

  • June 16- Medtronic Inc's $43 billion deal for Dublin- based Covidien Plc should accelerate already intense efforts by medical device rivals to seek merger partners, industry analysts and bankers said on Monday.

  • *China launches anti-dumping probe into dialysis kit makers. SHANGHAI, June 13- China on Friday launched an anti-dumping investigation into makers of blood dialysis equipment in the European Union and Japan, including market leader Fresenius Medical Care AG& Co KGaA, challenging the international firms who currently dominate the global and Chinese markets.

  • Lightning Round: Bristol-Myers, Safeway & more Wednesday, 11 Jun 2014 | 6:50 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Citigroup, Veeva & More Monday, 2 Jun 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • 3 firms unleashing big value: Cramer Monday, 14 Apr 2014 | 6:29 PM ET

    Jim Cramer says 3 companies are actively unlocking serious value right now.

  • Lightning Round: Citigroup, Disney & More Wednesday, 9 Apr 2014 | 6:45 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

  • March 28- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. It affects about 4,000 people in the United States and 25,000 worldwide.

  • March 27- Baxter International Inc said it would spin off its biotechnology operations into a publicly traded company by the middle of next year, leaving behind its core medical technology business.

  • March 27- Healthcare company Baxter International Inc said on Thursday it would separate into two companies, one that focuses on biotechnology and the other devoted to medical equipment. The company said its biotech business had 2013 revenue of $6 billion while medical products and equipment sales were $9 billion.

  • Early movers: LULU, C, BAC, YHOO, TWTR, SIG & more Thursday, 27 Mar 2014 | 7:41 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.